Physician profile
Paula Ronjon
NPI 1104882406
$1,126.59
in general payments reported to CMS, 2019-2025
14 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2021: $78.88 · 2022: $184 · 2023: $211 · 2024: $91.09 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.75 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.73 | 2021-2025 | Enhertu |
| Genentech USA, INC. | $135.00 | 2019 | |
| Exelixis INC. | $110.00 | 2019 | |
| Glaxosmithkline, LLC. | $96.90 | 2023 | Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $95.89 | 2023 | |
| Alexion Pharmaceuticals, INC. | $89.99 | 2025 | Soliris |
| Lilly USA, LLC | $84.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $72.84 | 2024-2025 | Opdivo |
| Nuvasive, INC. | $71.05 | 2019-2022 | |
| Foundation Medicine, INC. | $59.00 | 2019 | |
| Celgene Corporation | $34.49 | 2023-2024 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $23.86 | 2024 | |
| Pfizer INC. | $11.96 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Ronjon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.